Home / Insights / Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

31 October 2013

Posted in — OneVentures

Share

Learn More

Share

You may also like

02 August 2020

OneVentures

FDA Approves Xeglyze™ for the topical treatment of head lice infestation


02 August 2020

OneVentures

Hatchtech gets lice treatment nod from FDA


01 February 2018

OneVentures

No nit picking: Head lice group Hatchtech gets green light to trials


View All

Ventured. Gained.
decor